Clinical trial · Observational
Comorbidity Burden and Use of Concomitant Medications at CML Diagnosis
Comorbidity Burden and Use of Concomitant Medications at CML Diagnosis: A Retrospective Analysis of 527 Patients From the Polish Adult Leukemia Group Registry
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of the retrospective study was to further characterize the prevalence of comorbid conditions as well as the use of concomitant medications in newly diagnosed CML patients in a real-world setting. Hematologists from ten Polish hematological tertiary care centers were asked to analyze medical records for all consecutive CML patients diagnosed with chronic phase CML between January 1st 2005 and December 31st 2014.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Myeloid Leukemia | Chronic Myeloid Leukemia, BCR-ABL1 Positive | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| the prevalence of comorbid conditions | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- newly diagnosed CML patients
- interventionNames
- Other: the prevalence of comorbid conditions
Primary outcomes (2)
- measure
- the prevalence of comorbid conditions in newly diagnosed CML patients
- timeFrame
- February - July 2016
- description
- data collected through an on-line questionnaire, descriptive data
- measure
- the number of concomitant medications in newly diagnosed CML patients
- timeFrame
- February - July 2016
- description
- data collected through an on-line questionnaire, descriptive data
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * 1\) age ≥ 18 years; 2) diagnosis of chronic phase CML between January 1st 2005 and December 31st 2014. Exclusion Criteria: * primary diagnosis of CML in accelerated or blastic phase
References
Publications (1)
- RESULTGora-Tybor J, Sacha T, Waclaw J, Niesiobedzka-Krezel J, Grzybowska-Izydorczyk O, Medras E, Deren-Wagemann I, Patkowska E, Seferynska I, Lewandowski K, Wache A, Blajer-Olszewska B, Watek M, Kotwica-Mojzych K, Wasilewska E, Warzocha K, Jamroziak K. Comorbidity Burden and Use of Concomitant Medications at CML Diagnosis: A Retrospective Analysis of 527 Patients From the Polish Adult Leukemia Group Registry. Clin Lymphoma Myeloma Leuk. 2018 Jul;18(7):e283-e285. doi: 10.1016/j.clml.2018.05.001. Epub 2018 May 9. No abstract available. PMID 29778693